Treatment of follicular lymphoma: current status
H Tilly, A Zelenetz - Leukemia & lymphoma, 2008 - Taylor & Francis
With the recent proliferation of treatment options for patients with follicular lymphoma (FL),
median survival has been shown to have improved, from 84 months between 1983 and …
median survival has been shown to have improved, from 84 months between 1983 and …
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry
M Provencio, P Sabín, J Gomez-Codina, M Torrente… - PloS one, 2017 - journals.plos.org
Background Follicular lymphoma is the second most common non-Hodgkin lymphoma in the
United States and Europe. However, most of the prospective randomized studies have very …
United States and Europe. However, most of the prospective randomized studies have very …
Long‐term follow‐up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma
R Puckrin, N Chua, K Chin, A Peters… - British Journal of …, 2023 - Wiley Online Library
Although autologous stem cell transplantation (ASCT) can achieve durable responses in
eligible patients with follicular lymphoma (FL), long‐term follow‐up is needed to determine if …
eligible patients with follicular lymphoma (FL), long‐term follow‐up is needed to determine if …
Sequencing of therapies in relapsed follicular lymphoma
LJ Nastoupil, CR Flowers… - Hematology 2014, the …, 2018 - ashpublications.org
Follicular lymphoma (FL) is an incurable but treatable disease with vast treatment options.
Despite the abundance of efficacious treatment modalities, there is no universally agreed …
Despite the abundance of efficacious treatment modalities, there is no universally agreed …
Multicenter analysis of advanced stage grade 3A follicular lymphoma outcomes by frontline treatment regimen
Background Follicular lymphoma (FL) is a common form of non-Hodgkin lymphoma with a
wide spectrum of presentation. While grade 1/2 FL is considered low grade and grade 3B FL …
wide spectrum of presentation. While grade 1/2 FL is considered low grade and grade 3B FL …
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall
survival (OS). Here we assessed if early events as defined by event‐free survival (EFS) at 12 …
survival (OS). Here we assessed if early events as defined by event‐free survival (EFS) at 12 …
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial
HC Schouten, W Qian, S Kvaloy, A Porcellini… - Journal of clinical …, 2003 - ascopubs.org
Purpose: To determine, in a randomized clinical trial, whether high-dose therapy (HDT)
followed by autologous stem-cell transplantation is more effective than standard treatment …
followed by autologous stem-cell transplantation is more effective than standard treatment …
[HTML][HTML] Current trends in diagnosis and management of follicular lymphoma
G Gupta, V Garg, S Mallick, A Gogia - American Journal of Blood …, 2022 - ncbi.nlm.nih.gov
Follicular lymphoma (FL) originates from germinal center B cells, is the most prevalent form
of indolent non-Hodgkin's lymphoma. Upfront management is based on stage, grade, and …
of indolent non-Hodgkin's lymphoma. Upfront management is based on stage, grade, and …
Rituximab extended schedule or re-treatment trial for low–tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402
BS Kahl, F Hong, ME Williams… - Journal of Clinical …, 2014 - ascopubs.org
Purpose In low–tumor burden follicular lymphoma (FL), maintenance rituximab (MR) has
been shown to improve progression-free survival when compared with observation. It is not …
been shown to improve progression-free survival when compared with observation. It is not …
Combination biologic therapy as initial treatment for follicular lymphoma: initial results from CALGB 50701-a phase II trial of extended induction epratuzumab (anti …
B Grant, JP Leonard, JL Johnson, L Kostakoglu, E Hsi… - Blood, 2010 - Elsevier
Abstract 427 Rituximab is effective as single agent therapy in the treatment of follicular
lymphoma (FL), and when combined with chemotherapy has extended remissions and …
lymphoma (FL), and when combined with chemotherapy has extended remissions and …